Ventricular arrhythmias in Kearns-Sayre syndrome: A cohort study using the National Inpatient Sample database 2016-2019.
Kearns-Sayre syndrome
conduction defects
implantable cardioverter-defibrillator
myotonic dystrophy
pacemaker
ventricular tachycardia
Journal
Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
05
09
2022
received:
06
04
2022
accepted:
02
10
2022
pubmed:
9
10
2022
medline:
15
12
2022
entrez:
8
10
2022
Statut:
ppublish
Résumé
Degeneration of the cardiac conduction system resulting in complete heart block (CHB), ventricular arrhythmias (VA), and sudden cardiac death (SCD) is recognized in patients with Kearns-Sayre syndrome (KSS) and is potentially preventable with permanent pacemaker (PPM) implantation. However, other mechanisms for SCD have been proposed, and the efficacy of implanting a defibrillator instead of PPM remains to be investigated. We utilized the National Inpatient Sample (NIS) database 2016-2019 to investigate the risk of VA or dysrhythmic cardiac arrest (dCA) in KSS patients. We compared the outcomes of KSS to myotonic dystrophy (MD), a more common genetic disorder with similar clinical cardiac features and course. We identified 640 admissions for KSS. VA or dCA were lower in admissions for KSS than MD patients (2.3% vs. 4.5%, p = .009). Device implantation differed between study groups. Approximately, 70% of cases with KSS and conduction abnormalities had pacemaker (± defibrillator) on hospital discharge, compared to 35% in MD. Conduction abnormalities were associated with higher rates of VA or dCA in both study groups. None of the admissions for KSS patients who developed VA or dCA had a pacemaker, and all of them had conduction abnormalities. One-third of admissions for MD patients who developed VA or dCA had a device already implanted prior to the event. Despite its effectiveness in preventing VA, PPM remains underutilized in patients with KSS or MD who have conduction abnormalities. PPM alone do not fully prevent VA in MD patients; therefore, addition of defibrillator capacity might be necessary.
Sections du résumé
BACKGROUND
Degeneration of the cardiac conduction system resulting in complete heart block (CHB), ventricular arrhythmias (VA), and sudden cardiac death (SCD) is recognized in patients with Kearns-Sayre syndrome (KSS) and is potentially preventable with permanent pacemaker (PPM) implantation. However, other mechanisms for SCD have been proposed, and the efficacy of implanting a defibrillator instead of PPM remains to be investigated.
METHODS
We utilized the National Inpatient Sample (NIS) database 2016-2019 to investigate the risk of VA or dysrhythmic cardiac arrest (dCA) in KSS patients. We compared the outcomes of KSS to myotonic dystrophy (MD), a more common genetic disorder with similar clinical cardiac features and course.
RESULTS
We identified 640 admissions for KSS. VA or dCA were lower in admissions for KSS than MD patients (2.3% vs. 4.5%, p = .009). Device implantation differed between study groups. Approximately, 70% of cases with KSS and conduction abnormalities had pacemaker (± defibrillator) on hospital discharge, compared to 35% in MD. Conduction abnormalities were associated with higher rates of VA or dCA in both study groups. None of the admissions for KSS patients who developed VA or dCA had a pacemaker, and all of them had conduction abnormalities. One-third of admissions for MD patients who developed VA or dCA had a device already implanted prior to the event.
CONCLUSION
Despite its effectiveness in preventing VA, PPM remains underutilized in patients with KSS or MD who have conduction abnormalities. PPM alone do not fully prevent VA in MD patients; therefore, addition of defibrillator capacity might be necessary.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1357-1363Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep. 2010;10:118-126. http://www.ncbi.nlm.nih.gov/pubmed/20425236
Kabunga P, Lau AK, Phan K, et al. Systematic review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial cytopathy. Int J Cardiol. 2015;181:303-310. http://www.ncbi.nlm.nih.gov/pubmed/25540845
Agrawal H, Ekhomu O, Choi HW, Naheed Z. Natural history of conduction abnormalities in a patient with Kearns-Sayre syndrome. Pediatr Cardiol. 2013;34:1044-1047. http://www.ncbi.nlm.nih.gov/pubmed/22614904
van Beynum I, Morava E, Taher M, et al. Cardiac arrest in Kearns-Sayre syndrome. JIMD Rep. 2012;2:7-10. http://www.ncbi.nlm.nih.gov/pubmed/23430846
Young TJ, Shah AK, Lee MH, Hayes DL. Kearns-Sayre syndrome: a case report and review of cardiovascular complications. Pacing Clin Electrophysiol. 2005;28:454-457. http://www.ncbi.nlm.nih.gov/pubmed/15869681
Puri A, Pradhan A, Chaudhary G, Singh V, Sethi R, Narain VS. Symptomatic complete heart block leading to a diagnosis of Kearns-Sayre syndrome. Indian Heart J;64:515-517. http://www.ncbi.nlm.nih.gov/pubmed/23102393
Pelargonio G, Dello Russo A, Sanna T, De Martino G, Bellocci F. Myotonic dystrophy and the heart. Heart. 2002;88:665-670. http://www.ncbi.nlm.nih.gov/pubmed/12433913
Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74:9320-9387. http://www.ncbi.nlm.nih.gov/pubmed/30412710
Members WritingCommittee, MJ Silka, Shah MJ, et al. 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: executive summary. Hear Rhythm. 2021;18:1925-1950. http://www.ncbi.nlm.nih.gov/pubmed/34363987
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Gui. Hear Rhythm. 2018;15:e190-252. http://www.ncbi.nlm.nih.gov/pubmed/29097320
Imamura T, Sumitomo N, Muraji S, et al. The necessity of implantable cardioverter defibrillators in patients with Kearns-Sayre syndrome - systematic review of the articles. Int J Cardiol. 2019;279:105-111. http://www.ncbi.nlm.nih.gov/pubmed/30642644
Krishna MR. Kearns Sayre Syndrome: looking beyond A-V conduction. Indian Pacing Electrophysiol J. 2017;17:78-80. http://www.ncbi.nlm.nih.gov/pubmed/29073001
Subbiah RN, Kuchar D, Baron D. Torsades de pointes in a patient with Kearns-Sayre syndrome: a fortunate finding. Pacing Clin Electrophysiol. 2007;30:137-139. http://www.ncbi.nlm.nih.gov/pubmed/17241330
Houchens RL, Ross DEA. Using the HCUP National Inpatient Sample to Estimate Trends. [Internet]. 2015. Available from: https://www.hcup-us.ahrq.gov/reports/methods/2006_05_NISTrendsReport_1988-2004A.pdf
Dong Y, Peng C-YJ. Principled missing data methods for researchers. Springerplus. 2013;2:222. http://www.ncbi.nlm.nih.gov/pubmed/23853744
Khambatta S, Nguyen DL, Beckman TJ, Wittich CM. Kearns-Sayre syndrome: a case series of 35 adults and children. Int J Gen Med. 2014;7:325-332. http://www.ncbi.nlm.nih.gov/pubmed/25061332
Hayes DL, Hyberger LKHDO. Incidence of conduction system disease and need for permanent pacemaker in patients with Kearns Sayre syndrome. PACE. 2001;24(4 part II):576.
Di Mambro C, Tamborrino PP, Silvetti MS, et al. Progressive involvement of cardiac conduction system in paediatric patients with Kearns-Sayre syndrome: how to predict occurrence of complete heart block and sudden cardiac death. Europace. 2021;23:948-957. http://www.ncbi.nlm.nih.gov/pubmed/33336258
Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA. 2012;307:1292-1301. http://www.ncbi.nlm.nih.gov/pubmed/22453570
Oginosawa Y, Abe H, Nagatomo T, Mizuki T, Nakashima Y. Sustained polymorphic ventricular tachycardia unassociated with QT prolongation or bradycardia in the Kearns-Sayre syndrome. Pacing Clin Electrophysiol. 2003;26:1911-1912. http://www.ncbi.nlm.nih.gov/pubmed/12930512
Finsterer J. Cardiac disease in Kearns-Sayre syndrome requires comprehensive management. Cardiol Young. 2019;29:1118-1119. http://www.ncbi.nlm.nih.gov/pubmed/31270000
Wilmin S, De Bels D, Knecht S, Gottignies P, Gazagnes M-D, Devriendt J. Torsade de pointes in Kearns-Sayre syndrome. Pract Neurol. 2012;12:199-201. http://www.ncbi.nlm.nih.gov/pubmed/22661355
Shah MJ, Silka MJ, Silva JNA, et al. 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients. Cardiol Young. 2021;31:1738-1769. http://www.ncbi.nlm.nih.gov/pubmed/34338183